Observational studyClinical rheumatology2016
Influence of urate-lowering therapies on renal handling of uric acid.
Observational study in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Trial
- Urate-lowering therapy modifies associations between urinary urate and kidney outcome.Renal failure · 2026Article
- Understanding Renal Tubular Function: Key Mechanisms, Clinical Relevance, and Comprehensive Urine Assessment.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- Association between urinary uric acid excretion and kidney outcome in patients with CKD.Scientific reports · 2024Article
- A highly sensitive dual-read assay using nitrogen-doped carbon dots for the quantitation of uric acid in human serum and urine samples.Mikrochimica acta · 2021Article
- Efficacy of different urinary uric acid indicators in patients with chronic kidney disease.BMC nephrology · 2020Article
- The Role of a "Treat-to-Target" Approach in the Long-Term Renal Outcomes of Patients with Gout.Journal of clinical medicine · 2019Article
- Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients.BMC nephrology · 2019Article
- The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.Clinical and experimental nephrology · 2019Article
- Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.JAMA internal medicine · 2018Article
- Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.Clinical rheumatology · 2018Observational
- Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.BMC nephrology · 2018Article
- The Dietary Fructose:Vitamin C Intake Ratio Is Associated with Hyperuricemia in African-American Adults.The Journal of nutrition · 2018Article
- Physiology of Hyperuricemia and Urate-Lowering Treatments.Frontiers in medicine · 2018Review
- Management of Gout and Hyperuricemia in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.Oncotarget · 2017Article
- Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine.Clinical rheumatology · 2016Article
- Clinical, Genetic, and Urinary Factors Associated with Uromodulin Excretion.Clinical journal of the American Society of Nephrology : CJASN · 2016Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to investigate the effect of urate-lowering therapies (ULTs) on renal uric acid excretion in gout patients. This prospective observational study involved 106 primary gout patients and 51 healthy controls. Gout patients received ULT with either xanthine oxidase inhibitors or the uricosuric agent benzbromarone. Parameters such as 24-h urinary uric acid, creatinine clearance, uric acid clearance, glomerular filtration load of uric acid, fractional excretion of uric acid, excretion of uric acid per volume of glomerular filtration, and urinary uric acid to urinary creatinine ratio were used to evaluate the pre- and post-treatment renal capacity for uric acid clearance in gout patients and were compared with the values in the healthy controls. Compared to healthy controls, gout patients had higher glomerular filtration load of uric acid and lower uric acid clearance, creatinine clearance, and fractional uric acid excretion. After ULT, both the xanthine oxidase inhibitor group and benzbromarone group patients showed reduction in glomerular filtration load of uric acid. Creatinine clearance was significantly improved in the xanthine oxidase inhibitor group. Excretion function was remarkably enhanced in patients who reached the treatment target (serum uric acid <6 mg/dl). Changes in glomerular uric acid filtration load were significantly correlated with changes in serum urate levels. Gout patients have impaired renal uric acid excretion. ULTs reduce renal urate load and enhance the renal capacity of uric acid clearance. Xanthine oxidase inhibitors showed superiority over benzbromarone in improving renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.